Poland’s Quiet Pivot From Generics To Innovative Treatments

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.  

Flag of Poland, full background
An Appetite For Risk And More EU Funding Have Fueled Biotech Growth In Poland • Source: Shutterstock

Poland’s biopharma sector is best known for its strengths in generics and biosimilars, with companies like Polpharma SA providing central Europe and beyond with a reliable flow of affordable off-patent medications. However, some established companies are now developing innovative medicines, and a small list of biotech companies are creating the groundwork for a nascent biotech ecosystem.

The shift towards an innovative medicines sector has been gradual. Some generic drug manufacturers, like Celon Pharma S.A., have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.